CA2362577A1 - Ubiquinone qnfor the treatment of pains - Google Patents
Ubiquinone qnfor the treatment of pains Download PDFInfo
- Publication number
- CA2362577A1 CA2362577A1 CA002362577A CA2362577A CA2362577A1 CA 2362577 A1 CA2362577 A1 CA 2362577A1 CA 002362577 A CA002362577 A CA 002362577A CA 2362577 A CA2362577 A CA 2362577A CA 2362577 A1 CA2362577 A1 CA 2362577A1
- Authority
- CA
- Canada
- Prior art keywords
- ubiquinone
- pain
- treatment
- administration
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
The invention relates to ubiquinone Qn or ubiquinone Qn precursors that can be used in the treatment of pains.
Description
SMB
Ubiquinone 0" for the Treatment of Pain Ubiquinones are prenylated quinones which are wide-spread in the animal and vegetable kingdoms. They are derivatives of 2,3-dimethoxy-5-methyl-1,4-benzoquinone having linearly linked isoprene units in the 6-position.
Depending on the number of isoprene units, the ubiquinones are designated as Q-1, Q-2, Q-3 etc. In most mammals including humans, Q-10 (2,3-dimethoxy-S-methyl-6-deca-prenyl-1,4-benzoquinone) is prevailing. Ubiquinones serve as electron carriers in the respiratory chain, and they participate in the cyclic oxidation and reduction of substrates in the citric acid cycle. Ubiquinones Qn represent a precondition of the energy supply to all cells. The oxidative stress which arises, inter alia, from a high oxygen consumption causes damage to the membranes of mitochondria and cells which result in acute or degenerative disorders of the nervous system. The nervous system has a very high energy demand for the signal transduction by membrane potential build-up, ion-channel control, as well as by neuropeptide and neurotransmitter vesicle formation.
Ubiquinone Q-10 (also referred to as coenzyme Q-10) has previously been used in the therapy of heart diseases.
Surprisingly, it has now been found that ubiquinone Q~ and ubiquinone Q"
precur-sors can be used for the treatment of pain. Thus, they can also be used in methods for the preparation of agents for the treatment of pain.
The term "ubiquinone Q" precursors" refers to compounds which are converted to ubiquinone Qn in the body. These include, on the one hand, the ubihydroquinones, which are in an equilibrium with the ubiquinones, as well as simple esters of the ubihydroquinones with short-chained carboxylic acids having from 1 to 10 carbon _2_ atoms, for example, acetate, propionate or butyrate esters. These precursors are converted to the corresponding ubiquinones after the application thereof.
Ubiquinone Q-10 is preferably used because this is the main ubiquinone in humans.
According to the invention, there can be treated, in particular, pain caused by a disturbance in the stimulus conduction in the nerves, and/or are out of proportion with the external cause. This is pain for which either there is no external cause, or an excessive signal is produced upon a minor cause and under~oxidative stress conditions of the nerves.
The substances to be used according to the invention can be preferably employed for the treatment of pain which is caused by migraine, dialysis, herpes zoster, cancer, diabetic neuropathy, or generalized pain conditions. The treatment can be done by administration in oral, parenteral, local, inhalative or intranasal form. The kind of administration must be adapted to the .pain condition to be treated.
Thus, for example, it has been found that migraine can be treated even with high doses of Q-10 only with very limited success when oral administration is used.
However, when used in the form of oral and nasal sprays, small amounts are sufficient for a fast and effective elimination of migraine pain. Good results were achieved already with doses of about 20 mg.
In the case of herpes zoster, even the local application of Q-10 in the form of creams or gels has even proven useful. It is critical that sufficient amounts of the ubiquinones or ubiquinone precursors arrive at the place in which the pain caused by disturbances of the signal transmission of the nerve system has its origin.
By combination with lung surfactant factor (pulmonary surfactant factor) as described in WO 08/35660, this effect can even be enhanced.
In kidney dialysis patients, the administration of ubiquinone or its precursors before the dialysis causes the dialytic procedure to proceed in a tolerable way.
Due to the low dose which is already effective for treating migraine pain, the ubiquinone Q~ or its precursors are preferably used in the form of a spray, prefera-bly a nasal spray, according to the invention.
In principle, the single dose may be as high as 1,000 mg.
Ubiquinones are lipophilic substances which are virtually insoluble in water.
However, a particularly high effectiveness was found when the ubiquinone Qn or its precursors are in aqueous dispersion. Aqueous colloidal dispersions are particularly preferred. The preparation of the corresponding dispersions is described in WO
95/05164 and in the related DE-A-43 27 063.
Ubiquinone 0" for the Treatment of Pain Ubiquinones are prenylated quinones which are wide-spread in the animal and vegetable kingdoms. They are derivatives of 2,3-dimethoxy-5-methyl-1,4-benzoquinone having linearly linked isoprene units in the 6-position.
Depending on the number of isoprene units, the ubiquinones are designated as Q-1, Q-2, Q-3 etc. In most mammals including humans, Q-10 (2,3-dimethoxy-S-methyl-6-deca-prenyl-1,4-benzoquinone) is prevailing. Ubiquinones serve as electron carriers in the respiratory chain, and they participate in the cyclic oxidation and reduction of substrates in the citric acid cycle. Ubiquinones Qn represent a precondition of the energy supply to all cells. The oxidative stress which arises, inter alia, from a high oxygen consumption causes damage to the membranes of mitochondria and cells which result in acute or degenerative disorders of the nervous system. The nervous system has a very high energy demand for the signal transduction by membrane potential build-up, ion-channel control, as well as by neuropeptide and neurotransmitter vesicle formation.
Ubiquinone Q-10 (also referred to as coenzyme Q-10) has previously been used in the therapy of heart diseases.
Surprisingly, it has now been found that ubiquinone Q~ and ubiquinone Q"
precur-sors can be used for the treatment of pain. Thus, they can also be used in methods for the preparation of agents for the treatment of pain.
The term "ubiquinone Q" precursors" refers to compounds which are converted to ubiquinone Qn in the body. These include, on the one hand, the ubihydroquinones, which are in an equilibrium with the ubiquinones, as well as simple esters of the ubihydroquinones with short-chained carboxylic acids having from 1 to 10 carbon _2_ atoms, for example, acetate, propionate or butyrate esters. These precursors are converted to the corresponding ubiquinones after the application thereof.
Ubiquinone Q-10 is preferably used because this is the main ubiquinone in humans.
According to the invention, there can be treated, in particular, pain caused by a disturbance in the stimulus conduction in the nerves, and/or are out of proportion with the external cause. This is pain for which either there is no external cause, or an excessive signal is produced upon a minor cause and under~oxidative stress conditions of the nerves.
The substances to be used according to the invention can be preferably employed for the treatment of pain which is caused by migraine, dialysis, herpes zoster, cancer, diabetic neuropathy, or generalized pain conditions. The treatment can be done by administration in oral, parenteral, local, inhalative or intranasal form. The kind of administration must be adapted to the .pain condition to be treated.
Thus, for example, it has been found that migraine can be treated even with high doses of Q-10 only with very limited success when oral administration is used.
However, when used in the form of oral and nasal sprays, small amounts are sufficient for a fast and effective elimination of migraine pain. Good results were achieved already with doses of about 20 mg.
In the case of herpes zoster, even the local application of Q-10 in the form of creams or gels has even proven useful. It is critical that sufficient amounts of the ubiquinones or ubiquinone precursors arrive at the place in which the pain caused by disturbances of the signal transmission of the nerve system has its origin.
By combination with lung surfactant factor (pulmonary surfactant factor) as described in WO 08/35660, this effect can even be enhanced.
In kidney dialysis patients, the administration of ubiquinone or its precursors before the dialysis causes the dialytic procedure to proceed in a tolerable way.
Due to the low dose which is already effective for treating migraine pain, the ubiquinone Q~ or its precursors are preferably used in the form of a spray, prefera-bly a nasal spray, according to the invention.
In principle, the single dose may be as high as 1,000 mg.
Ubiquinones are lipophilic substances which are virtually insoluble in water.
However, a particularly high effectiveness was found when the ubiquinone Qn or its precursors are in aqueous dispersion. Aqueous colloidal dispersions are particularly preferred. The preparation of the corresponding dispersions is described in WO
95/05164 and in the related DE-A-43 27 063.
Claims (5)
1. Use of ubiquinone Q10 in the form of an aqueous colloidal dispersion for the treatment of pain.
2. The use according to claim 1, characterized in that said pain is caused by migraine, dialysis, herpes zoster, cancer, diabetic neuropathy, or general-ized pain conditions.
3. The use according to any of claims 1 or 2, characterized in that the treat-ment is done by administration in oral, parenteral, local, inhalative or intra-nasal form.
4. The use according to claim 3, characterized in that the administration is in the form of a spray.
5. The use according to claim 4, characterized in that the administration is in the form of a nasal spray.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19905879.2 | 1999-02-11 | ||
| DE19905879A DE19905879A1 (en) | 1999-02-11 | 1999-02-11 | Ubiquinon Qn used to treat pain |
| PCT/EP2000/001011 WO2000047192A2 (en) | 1999-02-11 | 2000-02-09 | UBIQUINONE QnFOR THE TREATMENT OF PAINS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2362577A1 true CA2362577A1 (en) | 2000-08-17 |
Family
ID=7897295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002362577A Abandoned CA2362577A1 (en) | 1999-02-11 | 2000-02-09 | Ubiquinone qnfor the treatment of pains |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1150682B1 (en) |
| AT (1) | ATE302009T1 (en) |
| CA (1) | CA2362577A1 (en) |
| DE (2) | DE19905879A1 (en) |
| DK (1) | DK1150682T3 (en) |
| ES (1) | ES2243243T3 (en) |
| WO (1) | WO2000047192A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018218287A1 (en) * | 2017-05-29 | 2018-12-06 | Woodlinda Pty Ltd | Treatment and/or prevention of neuropathic symptoms associated with diabetes mellitus type ii |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465517B1 (en) | 2000-07-11 | 2002-10-15 | N.V. Nutricia | Composition for the treatment of migraine |
| ATE480231T1 (en) | 2001-05-10 | 2010-09-15 | Kaneka Corp | COMPOSITIONS FOR TRANSMUCOSAL ADMINISTRATION WITH COENZYME Q AS THE ACTIVE INGREDIENT |
| EP1374883A1 (en) * | 2002-06-21 | 2004-01-02 | Roland. Dr. Lingg | Nasal spray containing a plant extract for the treatment of diseases such as herpes zoster, hematoma, mastitis and cardiovasculatory weakness |
| MX352315B (en) | 2006-05-02 | 2017-11-17 | Univ Miami | Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds. |
| MA52274A (en) | 2017-05-17 | 2021-02-24 | Berg Llc | USE OF COENZYME Q10 FORMULATIONS IN THE TREATMENT AND PREVENTION OF BUBBLE EPIDERMOLYSIS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6277318A (en) * | 1985-10-01 | 1987-04-09 | Eisai Co Ltd | Remedy for burn |
| JPH01165522A (en) * | 1987-12-23 | 1989-06-29 | M S C:Kk | Remedy for disease of nose or throat |
| DE4327063A1 (en) * | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenone particles with modified physicochemical properties |
| JP3612729B2 (en) * | 1994-04-12 | 2005-01-19 | 大正製薬株式会社 | Nourishing tonic |
| GB9601398D0 (en) * | 1996-01-24 | 1996-03-27 | Piper Edwina M | Composition |
| US6228891B1 (en) * | 1997-02-12 | 2001-05-08 | Mse Pharmazeutika Gmbh | Use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone |
| DE19905880A1 (en) * | 1999-02-11 | 2000-08-17 | Mse Pharmazeutika Gmbh | Spray containing ubiquinone Qn |
-
1999
- 1999-02-11 DE DE19905879A patent/DE19905879A1/en not_active Ceased
-
2000
- 2000-02-09 DK DK00914075T patent/DK1150682T3/en active
- 2000-02-09 AT AT00914075T patent/ATE302009T1/en active
- 2000-02-09 ES ES00914075T patent/ES2243243T3/en not_active Expired - Lifetime
- 2000-02-09 CA CA002362577A patent/CA2362577A1/en not_active Abandoned
- 2000-02-09 WO PCT/EP2000/001011 patent/WO2000047192A2/en active IP Right Grant
- 2000-02-09 DE DE50010972T patent/DE50010972D1/en not_active Expired - Lifetime
- 2000-02-09 EP EP00914075A patent/EP1150682B1/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018218287A1 (en) * | 2017-05-29 | 2018-12-06 | Woodlinda Pty Ltd | Treatment and/or prevention of neuropathic symptoms associated with diabetes mellitus type ii |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE302009T1 (en) | 2005-09-15 |
| ES2243243T3 (en) | 2005-12-01 |
| DE19905879A1 (en) | 2000-08-17 |
| DK1150682T3 (en) | 2005-12-19 |
| DE50010972D1 (en) | 2005-09-22 |
| WO2000047192A3 (en) | 2001-04-12 |
| EP1150682B1 (en) | 2005-08-17 |
| WO2000047192A2 (en) | 2000-08-17 |
| EP1150682A2 (en) | 2001-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040034107A1 (en) | Ubiquinone Qn for the treatment of pain | |
| US5268176A (en) | Method and compositions for the non-invasive treatment of telangiectasia | |
| CA2362577A1 (en) | Ubiquinone qnfor the treatment of pains | |
| CA2735293A1 (en) | Nadh and nadph therapeutic agents for dermal administration | |
| US20050019268A1 (en) | Spray containing ubiquinone Qn | |
| DE3235923C2 (en) | ||
| CA2617741A1 (en) | Horehound composition for reducing snoring, package and method | |
| BRPI0417123A (en) | prolonged release torsemide formulation | |
| Hommes | The role of the blood-brain barrier in the aetiology of permanent brain dysfunction in hyperphenylalaninaemia | |
| US20100104669A1 (en) | Method for preparing an aqueous solution containing triterpenic acid, aqueous solution containing triterpenic acid, and use thereof | |
| Yocca et al. | Effect of chronic lithium treatment on rat pineal rhythms: N-acetyltransferase, N-acetylserotonin and melatonin. | |
| CN110755573B (en) | A refreshing solution for inhalation and its preparation method | |
| CA2362575A1 (en) | Spray containing ubiquinone qn | |
| CN106667974A (en) | Preparation method of terbutaline sulfate solution for inhalation | |
| Brass et al. | Modulation of cerebral catecholamine concentrations during hyperphenylalaninaemia | |
| JP2001510026A (en) | Nutritional composition for patients under stress | |
| US20220313625A1 (en) | Pharmaceutical agent, medicinal solution for cleaning pulmonary alveoli, and nebulizer | |
| JP2005111139A (en) | Body wiper and wet wipe | |
| NO874241L (en) | THERAPEUTIC ACTIVE SALTS. | |
| KR20210127689A (en) | Composition for preventing or treating brain-nervous system diseases comprising RITA or derivatives thereof | |
| Hong et al. | Formulation, stability, and antitumor activity of 1-β-D-arabinofuranosylcytosine conjugate of thioether phospholipid | |
| Feet et al. | Cerebral excitatory amino acids and Na+, K+‐ATPase activity during resuscitation of severely hypoxic newborn piglets | |
| Scheer et al. | Creatine and creatine pyruvate reduce hypoxia-induced effects on phrenic nerve activity in the juvenile mouse respiratory system | |
| US3755599A (en) | Methods for relieving bronchospasm with prostaglandin a compounds | |
| DE10248601B4 (en) | Pharmaceutical agent for endonasal administration in the treatment of diseases and disorders of the central nervous system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |